Unknown and maybe the cheapest biotech you can get at this time . CTX has already 5 products on the market and another BIG product expect to be launched very soon in US and CA which is outlicensed to Taro Pharma a large pharma company . Another important point is that management and institutions bought massive shares in last weeks .This low float gem has everything to be the next 10+ bagger gem check it out guys before the stock gets discovered .glta Crescita Therapeutics (T.CTX) Market Cap: $ 8.4 Million Cash: $ 8.8 Million Price: 0.60 Shares Out: 14 Million Crescita targeting $50-million in revenue in 5 years........December 05, 2017 http://www.biotuesdays.com/features/2017/12/1/crescita-targeting-50-million-in-revenue-in-5-years Taro plans to launch Pliaglis in the U.S. in 2018, while Crescita is concurrently planning for the product’s Canadian launch and is currently seeking a licensing partner for the product in Mexico. Knight Therapeutics boosts Crescita holdings to 14.9%......2017-10-10 https://www.stockwatch.com/News/Item.aspx?bid=Z-C:GUD-2514098 "We are excited by Crescita's potential and expect only 'GUD' things to come from this investment," said Jonathan Ross Goodman, chief executive officer of Knight Therapeutics.
Technically, CTX.TO has been showing support at 0.53 and resistance at 0.73. Stochastic oscillator and RSI are triggering bullish signal.
